Biotechnology
January 21, 2013
Sanofi aims to be a major player in biotechnology.
The clinical breakthroughs made possible by biotechnology offer new hope for patients and are a powerful growth driver for sustainable innovation. We are committed to building new types of partnership with both the public and private sectors to attract external innovation, thereby making best use of our R&D expertise to become a leader in key technology platforms for the future of medicine: biotechnology and biotherapy. Between April 2009 and April 2010 the group's share of biotechnology-sourced products in its pharma portfolio (excluding vaccines) increased by 17% and in 2011 we enhanced our sustainable growth strategy by acquiring Genzyme.
Our aim is to exploit the potential of personalised healthcare. By taking a holistic approach to patient needs, we work to expand our product lines to cover each stage of a disease from prevention to various stages of treatment, complemented by services and technologies that boost therapeutic efficiency and monitoring capabilities to enhance patients' lives as a whole.
